The assessment of bronchial asthma pharmacotherapy effectiveness on the background correction of magnesium deficiency in children

Abstract

Aim: to evaluate the efficacy of pharmacotherapy of bronchial asthma in children with concomitant correction of magnesium deficiency. Material and Methods. A 12-week, prospective, randomized, open, comparative, parallel-group, which was included in the 50 children with uncontrolled and partially controlled atopic asthma and laboratory-confirmed magnesium deficiency. For the groups 1 and 2 it was assigned basic therapy of asthma in accordance with the recommendations of GINA (2011). In the group 1 it had been additionally performed concomitant correction of magnesium deficiency of Magnesium B6 Forte. There had been evaluated the effectiveness of a drug therapy for 12 weeks on the achieved level of asthma control, the frequency of exacerbations, the number of asymptomatic days. Dynamics of the severity of allergic inflammation was assessed by monthly monitoring of levels of nitric oxide in exhaled air (FeNO). Results. After 12 weeks of treatment, the magnesium content in erythrocytes in group 1 (1.79 (1,68-1,89) mmol / L) increased by 15.7% and was statistically significant (p <0,001) differed from group 2 (1.63 (1.57-1.68) mmol /L). By the end of the study the number of controlled asthma episodes in group 1 was significantly (p = 0.038) larger (20/25) than in group 2 (12/25), and the content of FeNO (19 (13-24) ppb) — significantly less (p = 0.013) than in control group (25 (21-30) ppb). Conclusion. The efficacy of pharmacotherapy of bronchial asthma in children is increased by the background correction of magnesium deficiency.

Keywords

• asthma
• asthma control
• children
• magnesium deficiency